News | December 06, 2024
Eugia Pharma receives USFDA approval for Pazopanib Tablets, 200 mg
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
Sitagliptin and Metformin Hydrochloride Tablets, 50 mg/500 mg and 50 mg/1000 mg are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
The product will be manufactured at Lupin’s Somerset facility in the US
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
This product will be manufactured at Lupin’s Nagpur facility in India
Subscribe To Our Newsletter & Stay Updated
